Pages that link to "Q44989661"
Jump to navigation
Jump to search
The following pages link to Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia (Q44989661):
Displaying 38 items.
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (Q22242958) (← links)
- Antibiotics for community-acquired pneumonia in adult outpatients (Q24193127) (← links)
- Antibiotics for community acquired pneumonia in adult outpatients (Q24240033) (← links)
- Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study (Q24813259) (← links)
- Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis (Q28291976) (← links)
- Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities (Q33848870) (← links)
- Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones (Q34143934) (← links)
- The antimicrobial resistance crisis: causes, consequences, and management (Q34192579) (← links)
- Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis (Q34232870) (← links)
- Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial (Q35531132) (← links)
- Development of quality indicators to evaluate antibiotic treatment of patients with community-acquired pneumonia in Indonesia (Q35531876) (← links)
- Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies (Q35867451) (← links)
- Clinical implications of macrolide resistance in community-acquired respiratory tract infections (Q36688947) (← links)
- Telithromycin in lower respiratory tract infections. (Q36895727) (← links)
- Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review (Q37045083) (← links)
- Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia (Q37116814) (← links)
- Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia (Q37193023) (← links)
- Effects of a Syndrome-Specific Antibiotic Stewardship Intervention for Inpatient Community-Acquired Pneumonia (Q37338130) (← links)
- Fastidious intracellular bacteria as causal agents of community-acquired pneumonia (Q37768416) (← links)
- Emerging drugs for pneumococcal pneumonia (Q37864327) (← links)
- Strategies for reduction in duration of antibiotic use in hospitalized patients (Q37867329) (← links)
- Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline) (Q37890576) (← links)
- Ketolides in the treatment of community-acquired respiratory tract infections: A review (Q38199663) (← links)
- Solithromycin: A novel ketolide antibiotic. (Q38692156) (← links)
- PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia (Q40122073) (← links)
- Telithromycin use and spontaneous reports of hepatotoxicity (Q40183865) (← links)
- Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae (Q42670642) (← links)
- The wobbly status of ketolides: where do we stand? (Q43408523) (← links)
- How far should we go in reducing the length of antibiotic therapy for community-acquired pneumonia? (Q44228349) (← links)
- Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin (Q46168968) (← links)
- Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia (Q46620650) (← links)
- 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial (Q49920815) (← links)
- Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia. (Q55039125) (← links)
- Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients (Q57160026) (← links)
- Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign (Q57294589) (← links)
- [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features] (Q79340135) (← links)
- Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults (Q89481185) (← links)
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America (Q90408426) (← links)